LG Life Science to export Factive technology

Published: 2002-10-24 06:58:00

Updated: 2002-10-24 06:58:00

LG Life Science said on October 22 that it signed with GeneSoft, an US bioventure firm, a strategic alliance agreement for the marketing of a novel quinolone antibiotic Factive it developed.

Under the agreement, GeneSoft is to pay US$40.50 million as a technology transfer fee and following the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK